<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951209</url>
  </required_header>
  <id_info>
    <org_study_id>01478</org_study_id>
    <nct_id>NCT01951209</nct_id>
  </id_info>
  <brief_title>Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis</brief_title>
  <official_title>Prospective Pilot Study of the Effect of Rifaximin on B-Cell Dysregulation in Cirrhosis Due to Chronic Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David E. Kaplan, MD MSc</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Corporal Michael J. Crescenz VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States&#xD;
      veterans. Cirrhosis is associated with impaired antibody responses and increased risk of&#xD;
      bacterial infections. We have recently identified that cirrhosis is associated with&#xD;
      abnormalities of memory B-cells, cells that make antibodies and help protect against&#xD;
      bacterial infections. We have identified that chemicals associated with gut bacteria might&#xD;
      play a role in causing these B-cell abnormalities. It is well known that gut bacteria have&#xD;
      increased access to the blood in individuals with cirrhosis, a process called bacterial&#xD;
      translocation. We hypothesize that reducing bacteria counts in the gut by using&#xD;
      poorly-absorbed antibiotics (also known as selective gut decontamination) will partially&#xD;
      reverse losses of memory B-cells in cirrhosis by reducing bacterial translocation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We intend to enroll 18 patients with cirrhosis who do not have hepatic encephalopathy to&#xD;
      prospectively evaluate the impact of rifaximin on B-cell phenotype and function. We plan to&#xD;
      employ a randomized, double-masked, prospective crossover design to minimize bias. Subjects&#xD;
      will be randomized to receive either rifaximin SSD 80mg or a matched placebo once daily for&#xD;
      12 weeks then crossed over to opposite therapy for 12 weeks. Serum and lymphocytes will be&#xD;
      collected at baseline and every 4 weeks for in vitro assessment markers of gut microbial&#xD;
      translocation and B-cell assays. Stool will be collected at baseline and every 12 weeks for&#xD;
      future evaluation of changes of the gut microbiome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate enrollment prior to expiration date of unreplaceable blinded investigational product&#xD;
  </why_stopped>
  <start_date type="Actual">November 17, 2016</start_date>
  <completion_date type="Actual">June 12, 2017</completion_date>
  <primary_completion_date type="Actual">November 17, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CD27+ B-cell frequency</measure>
    <time_frame>Week 0 (Baseline) to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in basal B-cell activation</measure>
    <time_frame>Week 0 to Week 12</time_frame>
    <description>5 x 104/well B-cells negatively selected from normal donor PBMC will be cultured in 50% RPMI 1640/50% cirrhotic patient serum for 48 hours. After 48 hours, B-cells will be assessed for activation markers such as HLA-DR geometric mean fluorescence intensity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in circulating markers of bacterial translocation</measure>
    <time_frame>Week 0 to Week 12</time_frame>
    <description>Plasma samples will be studied for sCD14 by ELISA, bacterial DNA by rtPCR of 16S ribosomal RNA using established techniques, and Limulus Amebocyte Lysate Assay</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Rifaximin/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Rifaximin SSD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>550mg orally twice daily for 12 weeks</description>
    <arm_group_label>Placebo/Rifaximin SSD</arm_group_label>
    <arm_group_label>Rifaximin/Placebo</arm_group_label>
    <other_name>Rifaximin (Xifaxan)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Placebo/Rifaximin SSD</arm_group_label>
    <arm_group_label>Rifaximin/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current or prior chronic Hepatitis C infection as documented by detectable HCV RNA in&#xD;
             prior 5 years&#xD;
&#xD;
          -  Child-Turcotte-Pugh stage A5-B8. Cirrhosis diagnosis may be based on either&#xD;
             histological criteria (an previous liver biopsy showing F4/4 or F5-6/6 fibrosis) or&#xD;
             clinical criteria (nodular liver on abdominal imaging, splenomegaly, thrombocytopenia,&#xD;
             spider telangiectasias, palmar erythema, ascites, varices).&#xD;
&#xD;
          -  Platelet count &lt; 175,000/ul&#xD;
&#xD;
          -  Subject capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active alcohol use &gt; 20g/d&#xD;
&#xD;
          -  Current or planned (within following 6 months) antiviral therapy for hepatitis C&#xD;
&#xD;
          -  HIV co-infection&#xD;
&#xD;
          -  Diagnosis of overt hepatic encephalopathy&#xD;
&#xD;
          -  Current lactulose use&#xD;
&#xD;
          -  Exposure to rifaximin, rifampin or rifabutin within 12 months&#xD;
&#xD;
          -  History of C. difficile colitis&#xD;
&#xD;
          -  History of adverse drug reaction or sensitivity to rifaximin, rifampin or rifabutin or&#xD;
             any inactive components of rifaximin&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Anemia with hemoglobin &lt; 10g/dl or hematocrit &lt; 30%&#xD;
&#xD;
          -  Chronic kidney disease with creatinine &gt; 2.1mg/dl&#xD;
&#xD;
          -  Total bilirubin &gt; 3.0g/dl&#xD;
&#xD;
          -  Active non-hepatic medical conditions such as congestive heart failure, chronic lung&#xD;
             disease requiring oxygen, coronary artery disease with unstable angina&#xD;
&#xD;
          -  Requirement for chronic immunosuppressive therapy such as corticosteroids,&#xD;
             cyclophosphamide, azathioprine, TNF-alpha antagonists&#xD;
&#xD;
          -  Chronic autoimmune diseases such as systemic lupus erythematosus and rheumatoid&#xD;
             arthritis&#xD;
&#xD;
          -  Post-liver transplantation status or anticipated liver transplantation within 6&#xD;
             months.&#xD;
&#xD;
          -  Systemic antimicrobial exposure within 30 days of planned Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Kaplan, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporal Michael J. Crescenz VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Doi H, Iyer TK, Carpenter E, Li H, Chang KM, Vonderheide RH, Kaplan DE. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-positive B-cell population. Hepatology. 2012 Mar;55(3):709-19. doi: 10.1002/hep.24689. Epub 2012 Jan 19.</citation>
    <PMID>21932384</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 20, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Corporal Michael J. Crescenz VA Medical Center</investigator_affiliation>
    <investigator_full_name>David E. Kaplan, MD MSc</investigator_full_name>
    <investigator_title>GI Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Human</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>B-cell</keyword>
  <keyword>Rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified primary data will be made available for verification</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>September 22, 2021</submitted>
    <returned>October 19, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

